ATNX
Price:
$0.2031
Market Cap:
$2.33M
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the comp...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2017-06-14
Stock Exchange
NASDAQ
Ticker
ATNX
According to Athenex, Inc.’s latest financial reports and current stock price. The company's current ROE is 21.51%. This represents a change of 5.35% compared to the average of 20.42% of the last 4 quarters.
The mean historical ROE of Athenex, Inc. over the last ten years is 106.50%. The current 21.51% ROE has changed -79.80% with respect to the historical average. Over the past ten years (40 quarters), ATNX's ROE was at its highest in in the December 2022 quarter at 442.19%. The ROE was at its lowest in in the June 2022 quarter at -201.37%.
Average
106.50%
Median
-74.63%
Minimum
-259.46%
Maximum
1.52%
Discovering the peaks and valleys of Athenex, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 7.05%
Maximum Annual ROE = 1.52%
Minimum Annual Increase = -125.75%
Minimum Annual ROE = -259.46%
Year | ROE | Change |
---|---|---|
2022 | 1.52% | 7.05% |
2021 | 21.26% | -125.75% |
2020 | -82.57% | 23.80% |
2019 | -66.69% | -20.86% |
2018 | -84.27% | -42.15% |
2017 | -145.68% | -43.85% |
2016 | -259.46% | 400.25% |
The current ROE of Athenex, Inc. (ATNX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
486.66%
5-year avg
261.80%
10-year avg
106.50%
Athenex, Inc.’s ROE is less than G1 Therapeutics, Inc. (26.28%), greater than Adverum Biotechnologies, Inc. (-65.14%), less than AVROBIO, Inc. (29.68%), greater than CytomX Therapeutics, Inc. (-41.34%), greater than Rubius Therapeutics, Inc. (-238.11%),
Company | ROE | Market cap |
---|---|---|
26.28% | $377.75M | |
-65.14% | $138.13M | |
29.68% | $5.24M | |
-41.34% | $82.95M | |
-238.11% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Athenex, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Athenex, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Athenex, Inc.'s ROE?
How is the ROE calculated for Athenex, Inc. (ATNX)?
What is the highest ROE for Athenex, Inc. (ATNX)?
What is the 3-year average ROE for Athenex, Inc. (ATNX)?
What is the 5-year average ROE for Athenex, Inc. (ATNX)?
How does the current ROE for Athenex, Inc. (ATNX) compare to its historical average?